Data analysis has been a major bottleneck and Genedata Expressionist is the only solution we found that can meet our high throughput needs.
Basel, Switzerland and Tokyo, Japan (PRWEB) February 16, 2010
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the Japanese research foundation RIKEN has chosen Genedata Expressionist® to support biomarker development for cancer research. The renowned government foundation is using proteome analysis and Mass Spectrometry (MS) to identify biomarkers to aid in the development of serum-based diagnostic methods.
“We generate huge volumes of MS data in our proteomics facility,” explained Dr. Koji Ueda, a project leader at the Laboratory for Biomarker Development at RIKEN. “Data analysis has been a major bottleneck and Genedata Expressionist is the only solution we found that can meet our high throughput needs.”
RIKEN’s biomarker development group is using the Refiner MS and Analyst modules from the Genedata Expressionist system for high throughput LC-MS-based proteomics data processing and analysis. Refiner MS processes thousands of samples and terabytes of raw MS data and combines intuitive visualization with sophisticated algorithms for peak intensity and alignment correction, detection, quantification and matching.
“In the field of Clinical Proteomics there has been a great need to quantitatively analyze as many clinical samples as possible because of individual variations, and we had problems with the alignment of such a huge amount of MS data. However, Refiner MS solved them for us,” continued Ueda. “Now, we can confidently quantify and identify peaks, which has improved our overall biomarker development. In addition, using Analyst we can focus on sophisticated statistical analysis tasks, which allow data-mining from all perspectives and help us find the best predictive biomarkers in human sera.”
“RIKEN is one of Japan’s leading research facilities and they are making great strides in discovering biomarkers for early cancer diagnosis and risk identification,” said Dr. Othmar Pfannes, CEO of Genedata. “We are honored to have Genedata Expressionist chosen as the computational solution for biomarker research at this prestigious institute, which underscores Genedata’s continuing expansion in Japan.”
About RIKEN Center for Genomic Medicine
Founded in 2000 as a part of Japan's Millennium Genome Project, the RIKEN Center for Genomic Medicine was known as the RIKEN SNP Research Center until it adopted its current name in 2008. The main aim of this center is to construct infrastructure for the realization of personalized medicine through the establishment of large-scale, high-throughput SNP genotyping technologies. Using these techniques, researchers systematically analyze SNPs in the human genome and search for disease-related genes, genes related to drug response and examine the effect of SNPs on gene function. http://www.src.riken.go.jp/english
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, and Genedata Expressionist® make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. http://www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.